VOR (STOCKS)
Vor Biopharma Inc. Common Stock
$23.430000
+1.090000 (+4.88%)
Prev close: $22.340000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Biotechnology
- CEO
- Jean-Paul Kress
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $1,438.36M
- Employees
- 168
- P/E (TTM)
- -0.27
- P/B (TTM)
- -6.08
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
5
Strong Buy
6
Buy
2
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Mar 2026 (Q1)
|
$-5.11 | $-0.79 | -4.3218 | -548.31% |
|
Dec 2025 (Q4)
|
$25.84 | $-1.69 | +27.5341 | +1,625.29% |
|
Sep 2025 (Q3)
|
$-3.33 | $-3.28 | -0.0455 | -1.39% |
|
Jun 2025 (Q2)
|
$-43.80 | $-8.86 | -34.9443 | -394.60% |
Financial Statements
| Revenues | $0.00 |
| Nonoperating Income/Loss | $774.86M |
| Operating Expenses | $147.08M |
| Research and Development | $76.85M |
| Other Operating Expenses | $70.23M |
| Operating Income/Loss | -$147.08M |
| Income/Loss From Continuing Operations After Tax | $627.78M |
| Income/Loss From Continuing Operations Before Tax | $627.78M |
| Net Income/Loss | $627.78M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | $627.78M |
| Net Income/Loss Available To Common Stockholders, Basic | $627.78M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | $180.18 |
| Diluted Earnings Per Share | $180.18 |
| Basic Average Shares | 58,845,735 |
| Diluted Average Shares | 58,845,735 |
| Assets | $481.05M |
| Current Assets | $475.11M |
| Cash | $466.10M |
| Prepaid Expenses | $5.88M |
| Other Current Assets | $3.13M |
| Noncurrent Assets | $5.95M |
| Fixed Assets | $648.00K |
| Other Non-current Assets | $5.30M |
| Liabilities | $681.25M |
| Current Liabilities | $24.81M |
| Accounts Payable | $4.00M |
| Wages | $4.72M |
| Other Current Liabilities | $16.10M |
| Noncurrent Liabilities | $656.44M |
| Equity | -$200.20M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | -$200.20M |
| Liabilities And Equity | $481.05M |
| Net Cash Flow From Operating Activities | -$140.09M |
| Net Cash Flow From Operating Activities, Continuing | -$140.09M |
| Net Cash Flow From Investing Activities | -$348.99M |
| Net Cash Flow From Investing Activities, Continuing | -$348.99M |
| Net Cash Flow From Financing Activities | $404.11M |
| Net Cash Flow From Financing Activities, Continuing | $404.11M |
| Net Cash Flow | -$84.96M |
| Net Cash Flow, Continuing | -$84.96M |
| Comprehensive Income/Loss | $626.85M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | $626.85M |
| Other Comprehensive Income/Loss | -$813.62M |
| Other Comprehensive Income/Loss Attributable To Parent | -$936.00K |